

January 30, 2001

Zenith Goldline Pharmaceuticals, Inc.
Attention: Patricia Jaworski
140 Legrand Avenue
Northvale, NJ 07647

Dear Madam:

This is in reference to your abbreviated new drug application dated April 7, 1999, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Terazosin Hydrochloride Capsules, 1 mg (base), 2 mg (base), 5 mg (base), and 10 mg (base).

Reference is also made to your amendments dated June 4, July 30, August 19, and September 21, 1999; December 14, 2000; and January 12, 2001.

As noted in the Agency's publication entitled "Approved Drug Products with Therapeutic Equivalence Evaluations", also known as the "Orange Book", the listed drug product (RLD) referenced in your application, Hytrin Capsules of Abbott Laboratories, is subject to periods of patent protection which expire on June 29, 2010 (U.S. Patent No. 5,212,176), and April 29, 2013 (U.S. Patent Nos. 5,504,207; 5,412,095; and 5,294,615). Your application contains patent certifications to each of these patents under Section 505(j)(2)(A)(vii)(IV) of the Act. Section 505(j)(5)(B)(iii) of the Act provides that approval of this abbreviated application shall be made effective immediately unless an action is brought for infringement of one or more of the patents which are the subject of the certifications. Such action must be brought prior to the expiration of forty-five days from the date the notice provided under paragraph (2)(B)(i) is received. You have notified FDA that Zenith Goldline Pharmaceuticals, Inc. (Zenith) has complied with the requirements of Section 505(j)(2)(B) of the Act and no action for patent infringement was brought against Zenith within the statutory forty-five day period.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Terazosin Hydrochloride Capsules, 1 mg (base), 2 mg (base), 5 mg (base), and 10 mg (base), to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Hytrin[®] Capsules, 1 mg (base), 2 mg (base), 5 mg (base), and 10 mg (base), respectively, of Abbott Laboratories). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy, which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Validation of the regulatory methods has not been completed. It is the policy of the Office not to withhold approval until the validation is complete. We acknowledge your commitment to satisfactorily resolve any deficiencies, which may be identified.

Sincerely yours,

Gary Buehler
Acting Director
Office of Generic Drugs
Center for Drug Evaluation and Research